Literature DB >> 32830282

Neoadjuvant Biologic Therapy in the Surgical Management of Patients with Hidradenitis Suppurativa: A Cohort Study.

Luis Salvador-Rodriguez1, Carlos Cuenca-Barrales, Salvador Arias-Santiago, Alejandro Molina-Leyva.   

Abstract

Entities:  

Keywords:  biological therapy; hidradenitis suppurativa; surgery; therapeutics; acne inversa

Mesh：

Substances：

Year:  2020        PMID： 32830282      PMCID： PMC9234998          DOI： 10.2340/00015555-3616

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  13 in total

Review 1.  Clinical practice. Hidradenitis suppurativa.

Authors:  Gregor B E Jemec
Journal:  N Engl J Med       Date:  2012-01-12       Impact factor: 91.245

Review 2.  Recurrence of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis.

Authors:  Ali Mehdizadeh; Paul G Hazen; Falk G Bechara; Nora Zwingerman; Marzyeh Moazenzadeh; Morteza Bashash; R Gary Sibbald; Afsaneh Alavi
Journal:  J Am Acad Dermatol       Date:  2015-11       Impact factor: 11.527

Review 3.  Peptide growth factors are multifunctional.

Authors:  M B Sporn; A B Roberts
Journal:  Nature       Date:  1988-03-17       Impact factor: 49.962

Review 4.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue.

Authors:  E J Kovacs
Journal:  Immunol Today       Date:  1991-01

5.  European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.

Authors:  C C Zouboulis; N Desai; L Emtestam; R E Hunger; D Ioannides; I Juhász; J Lapins; L Matusiak; E P Prens; J Revuz; S Schneider-Burrus; J C Szepietowski; H H van der Zee; G B E Jemec
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-01-30       Impact factor: 6.166

6.  Surgical Management of Hidradenitis Suppurativa: Outcomes of 590 Consecutive Patients.

Authors:  John J Kohorst; Christian L Baum; Clark C Otley; Randall K Roenigk; Louis A Schenck; John H Pemberton; Eric J Dozois; Nho V Tran; Alex Senchenkov; Mark D P Davis
Journal:  Dermatol Surg       Date:  2016-09       Impact factor: 3.398

7.  Hidradenitis suppurativa treated with wide excision and second intention healing: a meaningful local cure rate after 253 procedures.

Authors:  I E Deckers; Y Dahi; H H van der Zee; E P Prens
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-01-17       Impact factor: 6.166

8.  Hidradenitis suppurativa: a retrospective study of 846 Dutch patients to identify factors associated with disease severity.

Authors:  Anne M R Schrader; Inge E Deckers; Hessel H van der Zee; Jurr Boer; Errol P Prens
Journal:  J Am Acad Dermatol       Date:  2014-05-28       Impact factor: 11.527

Review 9.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part II: Topical, intralesional, and systemic medical management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

10.  Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study.

Authors:  L M Prens; J Huizinga; I C Janse; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-06-17       Impact factor: 6.166
View more
  1 in total

1.  Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan.

Authors:  Nobukazu Hayashi; Koremasa Hayama; Kenzo Takahashi; Ichiro Kurokawa; Masateru Okazaki; Tomoko Kashiwagi; Eri Iwashita; Tadashi Terui
Journal:  J Dermatol       Date:  2022-01-17       Impact factor: 3.468
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.